Publications

  1. Iniguez-Ariza NM, Ryder MM, Hilger CR, Bible KC. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer. Thyroid 2017 Jul; 27 (7):923-927 Epub 2017 May 31
    View PubMed
  2. French JD, Bible K, Spitzweg C, Haugen BR, Ryder M. Leveraging the immune system to treat advanced thyroid cancers. Lancet Diabetes Endocrinol 2017 Jun; 5 (6):469-481 Epub 2016 Oct 20
    View PubMed
  3. Chintakuntlawar AV, Rumilla KM, Smith CY, Jenkins SM, Foote RL, Kasperbauer JL, Morris JC, Ryder M, Alsidawi S, Hilger C, Bible KC. Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. J Clin Endocrinol Metab 2017 Jun 01; 102 (6):1943-1950
    View PubMed
  4. Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M. Pembrolizumab-induced thyroiditis. Comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 2017 May 09 [Epub ahead of print]
    View PubMed
  5. Merten MM, Castro MR, Zhang J, Durski J, Ryder M. Examining the Role of Preoperative Positron Emission TomographyComputerized Tomography in Combination with Ultrasonography in Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules. Thyroid 2017 Jan; 27 (1):95-102 Epub 2016 Dec 05
    View PubMed
  6. Espinosa De Ycaza AE, Lowe KM, Dean DS, Castro MR, Fatourechi V, Ryder M, Morris JC, Stan MN. Risk of Malignancy in Thyroid Nodules with Non-Diagnostic Fine-Needle Aspiration: A Retrospective Cohort Study. Thyroid 2016 Nov; 26 (11):1598-1604 Epub 2016 Oct 05
    View PubMed
  7. Kottschade L, Brys A, Peikert T, Ryder M, Raffals L, Brewer J, Mosca P, Markovic S, Midwest Melanoma Partnership. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res 2016 Oct; 26 (5):469-80
    View PubMed
  8. Bible KC, Ryder M. Mutated BRAF and personalised medicine in differentiated thyroid cancer. Lancet Oncol 2016 Sep; 17 (9):1181-3 Epub 2016 July 23
    View PubMed
  9. Bible KC, Ryder M. Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol 2016 Jul; 13 (7):403-16 Epub 2016 Mar 01
    View PubMed
  10. Bible KC, Chintakuntlawar AV, Ryder M. Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer. J Oncol Pract 2016 Jun; 12 (6):521-2
    View PubMed
  11. Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014 Apr; 21 (2):371-81 Epub 2014 Mar 07
    View PubMed
  12. Gustafson MP, Lin Y, Ryder M, Dietz AB. Strategies for improving the reporting of human immunophenotypes by flow cytometry. J Immunother Cancer 2014; 2:18 Epub 2014 June 18
    View PubMed
  13. Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr Relat Cancer. 2013 Oct; 20(5):659-67. Epub 2013 Aug 21
    View PubMed
  14. Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS One. 2013; 8(1):e54302. Epub 2013 Jan 23.
    View PubMed
  15. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011 Dec; 121(12):4700-11. Epub 2011 Nov 21
    View PubMed
  16. Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFbeta signaling. Oncogene. 2011 Jul 14; 30(28):3153-62. Epub 2011 Mar 07.
    View PubMed
  17. Heidi H, Gopalakrishna NI, Carlson DL, Stambuck H, Ryder M, Ganly, I. Functional glomus vagale: a case report illustrating diagnosis and management. Skull Base. 2010; 20:491-6.
  18. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009 Jun 1; 69(11):4885-93.
    View PubMed
  19. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008 Dec; 15(4):1069-74. Epub 2008 Aug 21
    View PubMed
  20. Ricarte-Filho JCM, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers by mass spectrometry reveals distinct roles for BRAF, PIK3CA and AKT1 in disease pathogenesis. Cancer Research. 2008; 69:4885-93.
  21. Ryder M, Nikiforov YE, Fagin JA. Follicular variant papillary thyroid carcinoma arising within an ovarian teratoma. Thyroid. 2007 Feb; 17(2):179-80.
    View PubMed
  22. D'Souza, MM, Carr, J. A Characterization of [125I]beta-endorphin binding sites in the rat caudal dorsomedial medulla. Peptides.1998;19:931-937.
  23. Carr, JA, D'Souza, MM, Elmore, AR, Lovering, AT, Reigel, CE. Alterations in brain and pituitary beta-endorphin content in genetically epilepsy-prone rats. Epilepsy Res.1998;31:113-122.